To identify factors responsible for the decline of plasma tissue-type plasminogen activator (t-PA)-specific activity that we have observed after infusions of the activator and to define the potential usefulness of selected variants of t-PA in obviating them in patients with infarction, serial plasma samples from patients (n =4) and rabbits (n = 15) given t-PA were assayed for total t-PA antigen, t-PA activity, and free as opposed to type-i plasminogen activator inhibitor (PAI-1)-complexed t-PA. In patients, attenuation of t-PA specific activity after infusions was evident with concentrations of total t-PA antigen that were as much as sevenfold greater than pretreatment values (62 compared with 9 ng/ml). Attenuation of t-PA activity corresponded with the disappearance of free t-PA from plasma and was associated with persistence of complexes of t-PA with PAI-1. In normal rabbits (n =4) given wild-type t-PA by bolus injection, PAI-1 activity was 4 ±1 arbitrary units/ml. Attenuation of t-PA activity was not evident until 60 minutes after injection at a time when total plasma t-PA antigen concentration was as low as 13±8 ng/ml. Under these conditions, plasma t-PA was composed predominantly of free t-PA.
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In rabbits (n= 5) given lipopolysaccharide to increase plasma PAI-1 activity to193±84 arbitrary units/ml, the specific activity of t-PA was attenuated as early as 15 minutes after injection at a time when total t-PA antigen concentration was as high as 164±79 ng/ml. As was the case with samples from patients, attenuation was associated with the disappearance of free t-PA and the persistence of complexes of t-PA with PAI-1. A genetically engineered variant of t-PA with comparable specific activity and a comparable rate constant of association with PAI-1 but designed to persist in the circulation manifested prolonged clearance from plasma of normal rabbits (n =3) (t112=24.6± 1.6 minutes compared with an a phase t112 of 1.9 minutes for wild-type t-PA). The variant lacked the epidermal growth factor and kringle one domains and contained a duplicated kringle two domain. In contrast to the case with wild-type t-PA when rabbits were given lipopolysaccharide to augment plasma PAI-1, attenuation of activity of the variant of t-PA was not evident until 60 minutes after injection at a time when the total plasma t-PA antigen concentration was 403 ±64 ng/ml (n =3). Thus, t-PA activity paralleled the concentration of free rather than total t-PA that is dependent upon clearance of free and complexed t-PA from the circulation and upon interactions with plasma protease inhibitors including PAI- longed, low-dose infusions of t-PA may reduce the related arteries.'-5 However, early thrombotic reocincidence of early reocclusion,9,10 their use entails an clusion after recanalization induced with t-PA and increased potential risk of bleeding" and consider-plasma from patients with acute myocardial infarction, producing dichotomies between t-PA antigen and activity after infusions of t-PA. 15 Thus, inactivation of t-PA by PAI-1 at sites of complex, atheromatous plaques may contribute to early reocclusion of the infarct-related artery after thrombolysis induced with t-PA. The present study was undertaken to define additional determinants of t-PA activity in plasma by administering t-PAs with distinctive characteristics to normal rabbits and to rabbits in which plasma PAI-1 activity had been increased by administration of lipopolysaccharide. The results indicate that the activity of t-PA in plasma is dependent on the concentration of free t-PA, a variable determined by the clearance of free and complexed t-PA from the circulation and by interactions of t-PA with plasma protease inhibitors, particularly PAI-1. Thus, both factors-interaction of t-PA with PAI-1 as well as with other protease inhibitors and the persistence of t-PA in the circulation per se-influence the time-activity curve of t-PA after administration of pharmacologic doses of the activator. Administration of a t-PA variant with a prolonged half-time of clearance elicits sustained t-PA activity when compared with wild-type t-PA because of the persistence of free t-PA in the circulation.
Methods

Materials
Human melanoma cell (Bowes) t-PA (predominantly single chain), human fibrinogen (greater than 90% clottable protein), human glu-plasminogen, and the synthetic chromogenic substrate D-Val-Leu-LyspNA (S-2251) were purchased from Helena Laboratories, Beaumont, Texas. Wild-type t-PA produced by recombinant DNA technology and expressed in a Chinese Hamster ovary cell system (80% single chain) was provided by Genentech, South San Francisco, California. This material has a general structure symbolized as F, E, K,, K2 4 ,xM PPACK and 400 kIU/ ml aprotinin to prevent formation of complexes with protease inhibitors and to prevent activation of plasminogen in vitro.17,18 Samples for assay of fibrinogen were collected in citrate tubes with PPACK (2 ,uM) but without aprotinin.
Samples from patients with acute myocardial infarction were collected as described previously,15 stored at -70°C, and supplemented to contain 400 kIU/ml aprotinin and 4 ,uM PPACK before immunoprecipitation and immunoblotting.
Determinations of Concentrations of t-PA Antigen in Plasma
An ELISA system developed by Bergsdorf et al19 with reagents supplied commercially by American Diagnostica was used to determine the concentration of t-PA antigen in plasma samples as described previously. 15 The ELISA was standardized with Bowes melanoma cell t-PA kindly provided by Professor Desire Collen, University of Leuven. Slopes of curves constructed by assaying serially diluted samples were identical for mutant and wildtype t-PA.
Determinations of t-PA Activity
Activity of t-PA was assayed in citrated, plateletpoor plasma samples spectrophotometrically with a modification of an assay developed by AnglesCano.20 Plasma samples were incubated in microtiter wells coated with fibrin monomer for 2 hours at 370 C. t-PA activity was determined with 0.2 uM glu-plasminogen and 1.0 mM S-2251 during 2 hours at 370 C and was compared with activity of concomitantly assayed standards in plasma and expressed as international units per ml (IU/ml). Functional activity of t-PA was calibrated with reference to the International Reference Preparation of t-PA (83/ 517) obtained from the National Institute for Biological Standards and Control, London, England.
Determinations ofActivity of PAI-1 PAI-1 activity was assayed spectrophotometrically in citrated, platelet-poor plasma samples with a modification of an assay developed by Chmielewska and Wiman2' as described previously.15 One arbitrary unit (AU) of PAI-1 was defined as the amount of activity that inhibits 1 IU of t-PA activity during 10 minutes. PAI-1 activity in each sample was determined with reference to a standard curve obtained with pooled human or rabbit plasma (depending on the type of sample being assayed) and expressed as arbitrary units per milliliter (AU/ml). The interassay coefficient of variation was 4.3%.
Rate constants of interaction of PAI-1 with wildtype and with mutant t-PA were determined from the semilog plots of the time-activity curves of each in experiments in which the plasminogen activators were incubated in inhibitor-rich plasma. The firstorder rate constant of disappearance of activity under initial conditions was used to calculate half-times of disappearance as described by Chmielewska et al. 22 
Iodination
Affinity purified donkey anti-goat IgG (100 ,g) in 0.010 M sodium phosphate buffer, pH 7.4, with 0.150 M NaCI (phosphate-buffered saline, PBS) was labeled with carrier free Na 1251 (0.250 mCi) by the chloramine-T method.23 Unincorporated iodine was removed by exclusion chromatography with Sephadex-G-10 in Poly-Prep columns equilibrated and eluted with PBS. Radiolabeled IgG had a specific activity of 2 x 106 cpm/lgg and was greater than 98% precipitable with 10% (wt/vol) trichloroacetic acid. Each preparation was used for no more than 10 days.
Immunoprecipitation
Immunoprecipitation was performed with affinity purified antibodies that were covalently coupled to activated microspheres through functional tosyl chloride groups.24 Monoclonal antibody to t-PA has been shown previously to interact similarly with free t-PA and with t-PA-PAI-1 complexes.25 Antibody (600 gg/ml) was covalently coupled to activated microspheres (1.3%, solid component) in 7.5 ml 0.125 M sodium borate buffer and mixed for 18 hours at room temperature. The microsphere suspension was subsequently centrifuged at 2,000g for 10 minutes. The supernatant fraction was discarded and resuspended in 8.0 ml 1.0 M ethanolamine HCI with 0.1% Tween 20, pH 9.5, and rotated for 6 hours at 25°C. Microspheres were centrifuged and resuspended in 6.0 ml 0.05 M Tris-HCl buffer, pH 7.5, with 0.1 M NaCI, 0.01% bovine serum albumin (wt/vol), and 0.01% Tween 20. Immunoprecipitation of human and rabbit plasma samples containing 400 kIU/ml aprotinin and 4 
Fibrin Autography
Fibrin autography was performed on sequential samples from patients and rabbits according to the method of Granelli-Pipereno and Reich27 as described previously.15 Autographs were photographed serially with a Polaroid camera.
Western Blotting
Immunoblots were performed with immunoprecipitates from serial plasma samples with a modification of the procedure described by Burnette.28 SDS-PAGE gels were equilibrated in transfer buffer (0.025 M Tris-HCl, 0.192 M glycine, and 10% methanol) for 30 minutes. Electrostatic transfer of immunoprecipitates to nitrocellulose was performed at 40 C with a Transblot system for 40 minutes at 100 V. After transfer, SDS-PAGE gels were stained with 0.02% Coomassie blue in 40% methanol and 10% acetic acid to monitor the efficiency of transfer. Immunoblotting was performed at 250 C. Membranes were blocked with 1% (wt/vol) bovine hemoglobin in 0.05 M Tris-HCl, 0.15 M NaCl, pH 7.5 (TBS), for 1 hour. Membranes were then incubated with 10 ,g/ml goat polyclonal antibody specific for t-PA (used also as the ELISA capture antibody) in TBS with 1% bovine hemoglobin for 1 hour followed by three washes with TBS for 10 minutes and treatment with 1251 donkey antigoat IgG (2 x 10' cpm/ml) in TBS with 1% bovine hemoglobin for 1 hour. Membranes were then washed three times with TBS with 0.01% Tween 80 for 10 minutes each and exposed to Kodak XAR film for 24 and 48 hours with two sheets of Cronex intensifying screen at -70°C. Laser densitometry (LKB Ultrascan XL, Piscataway, New Jersey) of autoradiograms within the linear range defined experimentally was used to quantify the percentage of total t-PA attributable to each band in reduced samples. Results were expressed in terms of total t-PA in the sample as assayed by ELISA. Disappearance rate constants and half-times of clearance were calculated by deconvolution of clearance curves as described previously. ' 
Results
Patients With Infarction Figure 1 illustrates the results of analysis of serial plasma samples from four patients with infarction who were given therapeutic infusions of t-PA (Activase) in doses of 60 mg in the 1st hour, 20 mg in the 2nd, and 5 mg in each of the next 4 hours. Attenuation of t-PA activity, which was defined as negligible activity compared with antigenic mass, was detected in plasma samples at the time of termination of infusions (6 hours) in three of four patients, when total t-PA antigen concentrations were still sevenfold greater than pretreatment values (62±24 vs. 9+3 ng/ml). These data are consistent with our previous findings in which overall fibrinolytic activity of euglobulin fractions was found to be markedly reduced after completion of infusions of t-PA.1" Mean PAI-1 activity in plasma from patients before infusion of t-PA was 6.7± 1.0 AU/ml. Fibrin autographs and immunoblots exhibited comparable ratios of free t-PA and t-PA inhibitor complexes in all samples assayed with both procedures under the experimental conditions used (Figure 2 ).
Before infusion, plasma t-PA circulated predominantly as a 100-kDa species verified to be t-PA complexed with PAI-1 by immunoprecipitation. In samples obtained during infusions, additional lytic zones appeared on fibrin autographs corresponding with molecular weights of approximately 45 Attenuation of t-PA activity was associated with the disappearance of free t-PA and the persistence of t-PA complexed with PAI-1 (100 kDa) (Figure 2 ). Under nonreducing conditions, 45-, 55-, and 116-kDa forms were present in the t-PA used for injection (Activase) in both patients and rabbits ( Figure  2 ). The 45-kDa species was estimated to constitute approximately 7% of the preparation from immunoblots of nonreduced samples that were not immunoprecipitated. Reducing conditions resulted in bands at 64, 34, and 28 kDa. Thus, the 45-kDa species appeared to represent a proteolytic product of predominantly two-chain t-PA. The 116-kDa band, which was not detected in samples from patients, immunoprecipitated with IgG specific for t-PA but not for PAI-1.
Characteristics of Wild-Type and Variant t-PA
Specific functional activity and first-order rate constants of interaction of wild-type and mutant t-PA with PAI-1 are shown in Table 1 . The two agents were quite similar with respect to both. However, as shown in the experiments described below, the variant exhibited significantly prolonged clearance in vivo in rabbits.
Results in Nornal Rabbits
Clearance curves of t-PA antigen and activity after bolus injection of wild-type or of variant t-PA in normal rabbits with plasma PAI-1 activity of 4±1 AU/mI are shown in Figure 3 . Clearance of wildtype t-PA antigen and t-PA activity was characteristically biexponential with a rapid a half-time of clearance (1.9±0.4 minutes) and a slower ,B halftime of clearance (14.6+2.8 minutes). Attenuation of the activity of wild-type t-PA was not evident until 60 minutes after injection at a time when concentrations of t-PA antigen had declined to 12±9 ng/ml. Immunoblots of corresponding plasma samples obtained after injection of native t-PA exhibited predominantly free t-PA (.95%). The ratio of single-to two-chain (64:34 kDa) species in reduced samples was similar to that in injectates.
Clearance of variant t-PA was monoexponential rather than biexponential during 60 minutes with a half-time of 24.6+1.6 minutes (Figure 3 ). Antigen concentrations in plasma 60 minutes after injection of variant t-PA were 36-fold greater (430 compared with 12 ng/ml) than values in normal rabbits given wild-type t-PA. Significantly higher concentrations of t-PA activity were detectable after 60 minutes in samples from normal rabbits given the variant compared with results in analogous samples from rabbits given the same dose of wild-type t-PA (140 compared with 1 IU/ml). As was the case in normal rabbits given wild-type t-PA, immunoblots of corresponding plasma samples obtained early after injection of the variant exhibited predominantly free t-PA.
Results in Rabbits Treated With Lipopolysacchande to Increase Plasma PAI-I Activity
To further define the dependence of t-PA activity on the concentration of free t-PA, wild-type or variant t-PA was administered by bolus injection intravenously to rabbits that had been pretreated with lipopolysaccharide to augment plasma PAI-1 activity. Intravenous administration of lipopolysaccharide resulted in a time-and dose-dependent increase of PAI-1 activity in keeping with results of other investigators.31 Thus, activity of PAI-1 was 193±84 AU/ml 4 hours after injection of 10 ,gg/kg lipopolysaccharide. Mean fibrinogen concentrations and platelet counts were unchanged from pretreatment values, and schistocytes were not detectable in peripheral blood smears visualized with Wright's stain.
Attenuation of t-PA activity was detected 15 minutes after injection of wild-type t-PA at a time when the concentration of t-PA antigen was still markedly elevated, averaging 164±79 ng/ml, as shown in Figure 4 . As was the case in patients, attenuation of t-PA activity was associated with the appearance of a 100-kDa band on fibrin autographs and on immunoblots of nonreduced samples that was not apparent in samples from normal animals ( Figure 5 Administration of variant t-PA to rabbits in which PAI-1 activity had been increased elicited sustained t-PA activity that was not evident in plasma samples from rabbits given wild-type t-PA. Attenuation of t-PA activity was not evident until 60 minutes after injection of the variant at a time when the total t-PA antigen concentration in plasma averaged 403±64 ng/ml (Figure 4) . The rate of decline of specific activity of variant t-PA in plasma with time were significantly less than that seen with wild-type t-PA, that is, 0.030 compared with 0.065 IU/ng/min (p<0.01) as shown in Figure 6 .
Determination of the Concentration of Free t-PA and its Relation to t-PA Activity Determinations in sequential samples of the concentration of free t-PA by laser densitometry of autoradiograms of Western blots from rabbits with elevated PAI-1 activity given wild-type t-PA indicated that the disappearance of t-PA activity was monoexponential and generally concordant with the clearance of free t-PA as shown in Figure 7 . Persistence of t-PA activity in rabbits given variant t-PA contrasted with the decline seen in rabbits given wild-type t-PA and was associated with persistence of free t-PA. The identification of a low molecular weight form of t-PA in injectates as well as in plasma from patients and rabbits given t-PA indicated that pro-VARIANT NATIVE 0,000 1,000- teolysis of the t-PA molecule may occur during processing of pharmacologic material-a potential determinant of heterogeneity of biologic behavior in addition to glycosylation and the ratio of single-to two-chain species in particular preparations. 16 Our results suggest that two-chain t-PA is the species predominantly affected by the proteolytic phenomenon responsible. Genetically engineered variants designed to preclude such effects of processing may exhibit other desirable properties as well, such as increased fibrin specificity. 45 Our findings suggest that the intensity and persistence of pharmacologic fibrinolysis is dependent on free rather than total t-PA. The concentration of free t-PA is determined by several factors including clearance from the circulation and interactions with plasma protease inhibitors, particularly PAI-1. Attenuation of t-PA activity after therapeutic infusions may contribute to early coronary reocclusion. Thus, selected variants of t-PA with prolonged half-times of clearance, "invisibility" to PAI-1, or both may be particularly useful in maintaining the patency of recanalized coronary arteries.
